Sign in
Taking peopleNo phase

Clinical Efectiveness of a Multiplex PCR-Based Rapid Diagnostic Method in Bloodstream Infections

Key facts

Who runs it
Istanbul Medipol University Hospital
Where
Türkiye1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
300 people, planned
Started
1 Jan 2026
Expected to end
1 Jan 2027
Type of study
Observational, 2 groups
Treatments tested
  • Multiplex PCR-Based Rapid Diagnostic Test
  • Standard Microbiological Diagnostic Methods
Record updated
13 February 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (10)Hide the full registry criteria

Who can take part

  • Age 18 years or older
  • Clinical suspicion of bloodstream infection
  • Positive blood culture signal
  • Patients managed in hospital wards or intensive care units
  • Ability to provide informed consent (patient or legally authorized representative)

Who cannot take part

  • Recurrent episode of the same bloodstream infection
  • Inadequate or insufficient blood culture sample for analysis
  • Refusal or inability to provide informed consent
  • Death within the first 24 hours after blood culture collection
  • Loss to follow-up during the study period

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Bloodstream infections or bacteremia and sepsis or fungemia

This trial is currently available in Türkiye.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Bloodstream infections (BSIs) are associated with high morbidity and mortality, and delays in initiating appropriate antimicrobial therapy significantly worsen clinical outcomes. Conventional culture-based microbiological methods require 24-72 hours to provide definitive pathogen identification and antimicrobial susceptibility results, often leading to prolonged use of broad-spectrum empirical therapy. Rapid multiplex PCR-based diagnostic tests have the potential to shorten diagnostic timelines by identifying pathogens and resistance genes within approximately one hour; however, data on their real-world clinical impact remain limited.

Read full original descriptionShow less

This prospective, randomized, controlled, single-center study aims to evaluate the clinical effectiveness and diagnostic performance of a multiplex PCR-based rapid diagnostic method applied directly to positive blood culture bottles in adult patients with bloodstream infections. A total of 300 patients (≥18 years) with positive blood culture signals will be randomized 1:1 to either a study group or a control group. In the study group, positive blood cultures will be analyzed using both standard microbiological methods and a multiplex PCR panel, while the control group will undergo standard microbiological diagnostics alone.

The primary endpoint is time to optimal antimicrobial therapy (OTT), defined as the time from blood culture collection to initiation of the narrowest-spectrum, guideline-recommended antimicrobial agent active against the identified pathogen. Secondary endpoints include time to effective antimicrobial therapy (ETT), time to pathogen identification, antimicrobial escalation or de-escalation rates, length of hospital stay, total duration of antimicrobial therapy, and 28-day all-cause mortality.

Clinical, demographic, and microbiological data will be collected prospectively, including comorbidity indices and severity scores. Randomization will be stratified by ICU versus ward admission, presence of neutropenia, and Charlson Comorbidity Index to ensure balanced groups. Diagnostic accuracy of the multiplex PCR panel will be assessed by calculating sensitivity, specificity, predictive values, and agreement with standard culture methods.

This study seeks to determine whether rapid multiplex PCR diagnostics can meaningfully improve antimicrobial stewardship and clinical outcomes in patients with bloodstream infections compared with conventional diagnostic workflows.

The 2 groups in the trial

  • Multiplex PCR Group

    Participants with positive blood culture signals undergo rapid multiplex PCR testing in addition to standard microbiological diagnostic methods. Results of the multiplex PCR assay are reported to the clinical team and may be used to guide antimicrobial management.

    Treatment: Multiplex PCR-Based Rapid Diagnostic Test and Standard Microbiological Diagnostic Methods

  • Standard Diagnostics Group

    Participants with positive blood culture signals receive standard microbiological diagnostic testing only, according to routine clinical practice.

    Treatment: Standard Microbiological Diagnostic Methods

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Evaluation of the Clinical Efectiveness of a Multiplex PCR-Based Rapid Diagnostic Method in Bloodstream Infections: A Prospective Randomized Controlled Study
Criteria questions
Built from NCT07408544, who can take part
Record updated
13 February 2026